百奥泰(688177.SH)：BAT1308注射液联合BAT4706注射液及注射用BAT8008治疗晚期实体瘤获批临床试验

Group 1 - The core point of the article is that Baiotai (688177.SH) has received approval from the National Medical Products Administration for its clinical trial application of BAT1308 injection combined with BAT4706 injection and BAT8008 injection for the treatment of advanced solid tumors [1] Group 2 - The approved clinical trial signifies a significant step forward for the company's research and development efforts in oncology [1] - The combination of these investigational drugs aims to address unmet medical needs in the treatment of advanced solid tumors [1] - This approval may enhance the company's position in the competitive biopharmaceutical market [1]